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Background: Grb2 (Growth factor receptor-bound protein 2) is a key adaptor protein in maintaining the ERK activity
via linking Sos1 (Son of sevenless homolog 1) or other proteins to activated RTKs, such as EGFR. Currently, little
knowledge is available concerning the post-translational modification (PTM) of Grb2 except for its phosphorylation.
Since emerging evidences have highlighted the importance of SUMOylation (Small ubiquitin-related modifier),
a reversible PTM, in modulating protein functions, we wondered if Grb2 could be SUMOylated and thereby influences
its functions especially involved in the Ras/MEK/ERK pathway.
Methods: SUMOylation of Grb2 was analyzed with the in vivo SUMOylation assay using the Ni2+-NTA affinity pulldown
and the in vitro E.coli-based SUMOylation assay. To test the ERK activity and cell transformation, the murine fibroblast
cell line NIH/3T3 and the murine colon cancer cell line CMT-93 were used for the experiments including Grb2
knockdown, ectopic re-expression, cell transformation and migration. Immunoprecipitation (IP) was employed for
seeking proteins that interact with SUMO modified Grb2. Xenograft tumor model in mice was conducted to verify that
Grb2 SUMOylation regulated tumorigenesis in vivo.
Results: Grb2 can be SUMOylated by SUMO1 at lysine 56 (K56), which is located in the linker region between the
N-terminal SH3 domain and the SH2 domain. Knockdown of Grb2 reduced the ERK activity and suppressed cell motility
and tumorigenesis in vitro and in vivo, which were all rescued by stable ectopic re-expression of wild-type Grb2 but not
the mutant Grb2K56R. Furthermore, Grb2 SUMOylation at K56 increased the formation of Grb2-Sos1 complex, which
sequentially leads to the activation of Ras/MEK/MAPK pathway.
Conclusions: Our results provide evidences that Grb2 is SUMOylated in vivo and this modification enhances ERK
activities via increasing the formation of Grb2-Sos1 complex, and may consequently promote cell motility,
transformation and tumorigenesis.
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SUMOylation is a post-translational modification featured
by covalent and reversible attachment of small ubiquitin-
like modifier (SUMO) to protein substrates at specific
lysine residues [1,2]. SUMOylation has emerged as an
important regulatory mechanism in many eukaryotic cell
processes and physiological events including sub-cellular
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unless otherwise stated.repair, cell cycle regulation and chromatin organization
[3-5], which are all involved in human disease pathogen-
esis including tumorigensis [6].
Growth factor receptor-bound 2 (Grb2) is a ubiqui-
tously expressed adaptor protein involved in several
tyrosine-kinase dependent signaling pathways [7]. Grb2
contains a structure with one Src homology 2 (SH2) do-
main flanked by two SH3 domains [8]. The SH2 domain
helps Grb2 interact directly with phosphorylated tyrosine
residues of receptor tyrosine kinases (e.g., EGFR, PDGFR)
and non-receptor tyrosine kinases (e.g., FAK, Bcr/Abl),. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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taining proline-rich motifs, such as Sos1 [9]. As a pivotal
signal adaptor protein, Grb2 contributes to cell prolifer-
ation and normal development by linking other pro-
teins to the membrane after the recruitment of activated
EGFR. Upon the activation of EGFR or other RTKs, Grb2
recruits Sos1 to the membrane to form Grb2-Sos1 com-
plex, which is crucial for signaling transduction and
sequentially leads to the activation of Ras/MEK/MAPK
(generally recognized as extracellular signal-regulated kin-
ase, ERK) [10].
In the last two decades, a major focus of Grb2 research
is to identify its new binding proteins and the roles
involved in classical or unconventional signaling pathways.
However, except for phosphorylations [11], other post-
translational modifications (PTM) of Grb2 and their func-
tions remain to be explored. In this study, we found that
Grb2 could be SUMOylated at K56, which facilitated the
binding of Grb2 to Sos1 and subsequently enhanced the
ERK activity. Our study reveals a new regulatory mech-
anism for Grb2-controlled ERK activity via SUMO-
dependent Grb2-Sos1 complex formation.Figure 1 Grb2 is SUMOylated in vivo and in vitro. (A) HEK293T cells we
HA-Ubc9. SUMOylated proteins were purified from cell lysates using Ni2+-N
by immunoblotting for the Flag tag. (B) His-SUMO1-conjugated proteins w
His-SUMO1, HA-Ubc9 or SENP1 and probed for Grb2. *indicates endogenou
HA-SUMO1 and Flag-Ubc9. Lysates were immunoprecipitated with anti-HA
with anti-Grb2 antibody. (D) The pE1E2S1 plasmid was co-transformed with
Proteins were purified with GST agarose beads followed by Western blottinResults
Grb2 is SUMOylated in vivo and in vitro
To investigate whether Grb2 could be SUMOylated in vivo,
we transiently transfected Flag-tagged Grb2 along with
His-tagged SUMO1 and HA-tagged SUMO E2 ligase
Ubc9 in HEK293T cells. Following the purification of
His-tagged SUMO1 conjugates with Ni2+-NTA agarose
beads as described in our previous studies [12,13],
Grb2 was detected with anti-Flag antibody in the cells
co-transfected with Ubc9 and SUMO1 but not in the
cells transfected with Flag-Grb2 alone (Figure 1A). Upon
the covalent linkage of SUMO1 to Grb2, the relative mo-
lecular mass of Flag-Grb2 shifted from 26 to 46 kDa.
Moreover, the SUMOylation of Grb2 was massively
weakened upon co-transfection of the SUMO decon-
jugase SENP1 (Figure 1B). Additionally, long exposure
of the membrane incubated with anti-Grb2 antibody
showed that endogenous Grb2 was also SUMOylated
(Figure 1B, lane 2 in the second panel). To further
confirm endogenous Grb2 is SUMOylated, HEK293T cells
were transfected with HA-SUMO1 and Flag-Ubc9, and
then the lysates were used for immunoprecipitation (IP).re transfected with Flag-Grb2 along with or without His-SUMO1 and
TA affinity pulldown (Ni-pulldown) and SUMOylated Grb2 was detected
ere purified by Ni-pulldown from HEK293T cells expressing Flag-Grb2,
s SUMOylated Grb2. (C) HEK293T cells were co-transfected with
(m) antibody or mouse IgG (as a control), and then immunoblotted
pGEX4T1 (GST) or pGEX4T1-Grb2 (GST-Grb2) into E.coli BL21(DE3).
g analysis.
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band was clearly detected by anti-Grb2 antibody when the
lysates were immunoprecipitated with anti-HA antibody
but not with anti-normal IgG.
We also examined the SUMOylation of Grb2 using
an in vitro E.coli-based SUMOylation assay by pE1E2S1
[14]. pE1E2S1 contains the linear fusion of Aos1/Uba2,
Ubc9 and SUMO1 gene coding sequences which can ex-
press in E.coli strain BL21(DE3) and modify the potential
substrate proteins with SUMO1. As shown in Figure 1D,
the SUMO1-GST-Grb2 with higher molecular weight of
approximately 70 kDa was detected in the E.coli trans-
formed with pE1E2S1 and GST-Grb2 (with an expected
size of 50 kDa) but not in the E.coli transformed withFigure 2 K56 is a critical site for Grb2 SUMOylation. (A) HEK293T cells w
without His-SUMO1 and HA-Ubc9. The in vivo SUMOylation assay using Ni2
sequence alignment of Grb2 partial sequences located between N-SH3 and
region (yellow) has been underlined. (C) HEK293T cells were transfected w
amount of His-SUMO1 and HA-Ubc9 plasmids. The levels of SUMOylation w
or GST-Grb2K56R was co-transformed with pE1E2S1 plasmid into BL21(DE3).pE1E2S1 and GST vector. Collectively, these data demon-
strated that Grb2 is a SUMOylated protein.
K56 is the major site for Grb2 SUMOylation
To identify the critical site(s) for Grb2 SUMOylation, we
analysed Grb2 mutants in which all 16 lysines were mu-
tated individually to arginines for SUMOylation identifi-
cation. As shown in Figure 2A, only the mutation of
Lys-56 (K56) significantly decreased the level of SUMOy-
lated Flag-Grb2, suggesting that Grb2 is mainly SUMOy-
lated at K56. Interestingly, K56 is located in the linker
region between the N-SH3 domain and the SH2 domain,
and K56 and its flanking sequences are highly conserved
among vertebrate and invertebrate (Figure 2B). We furtherere co-transfected with Flag-Grb2 wild-type or mutants along with or
+-NTA beads was conducted as described in Methods. (B) Amino acid
SH2 domains from different species. The conserved lysine in the linker
ith Flag-Grb2WT or Flag-Grb2K56R plasmid along with the increased
ere determined as described in Methods. (D) The plasmid GST-Grb2
Western blotting was conducted after GST pulldown.
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and Grb2K56R by increasing the amount of Ubc9 and
SUMO1 plasmids. As shown in Figure 2C, the SUMOyla-
tion of both Grb2WT and Grb2K56R were difficult to
be detected in the cells co-transfected with 2 μg of Ubc9
and SUMO1, whereas SUMOylation of Grb2K56R was still
very low and only about 10-12% modification compared
to that of Grb2WT in the cells co-transfected with 6 μg of
Ubc9 and SUMO1. To further confirm K56 is a major
SUMOylation site for Grb2, we also generated GST-
tagged Grb2WT and Grb2K56R for the in vitro E.coli-based
SUMOylation assay. The result showed that SUMOylation
of GST-Grb2K56R was reduced by 70-80% compared to
that of Grb2WT (Figure 2D). It should be noted that there
is still measurable SUMO-Grb2 when K56 was mutated,Figure 3 SUMOylation of Grb2 at K56 promotes cellular transformatio
NIH/3T3 cell lines generated by polyclonal lentiviral infections were determ
2 ml of medium containing 5% FBS with 0.35% agar at 5 × 104 cells/well an
(C) Vasculogenic mimicry assay for stable NIH/3T3 cell lines. Each cell line a
matrigel and photographs were taken with microscope 20 hours later. (D)
5 μg/ml of Doxycycline (Doxy) for 24 or 36 hours. The ERK activities were d
obtained with ImageJ V1.45 software, and the signals of phosphorylated Er
independent experiments.suggesting the possible existence of complementary/
additional SUMO sites.
SUMOylation of Grb2 is crucial for cellular transformation
Given that Grb2 acts as an oncogene in most mamma-
lian cancer development [15], we asked whether
SUMOylation of Grb2 is involved in the cellular trans-
formation. NIH/3T3 stable cell lines were generated by
polyclonal lentiviral infections with the Lenti-Vector
carrying Grb2WT or Grb2K56R. Two cell clones with the
comparable expression levels of Grb2WT and Grb2K56R
were chosen for the following experiments (Figure 3A).
To determine whether Grb2 SUMOylation affects the
transforming potential, a soft agar colony-forming assay
was carried out. As shown in Figure 3B, the coloniesn. (A) Comparable expression levels of Grb2WT and Grb2K56R in stable
ined by Western blotting. (B) Stable NIH/3T3 cell lines were seeded in
d layered onto the base. The photographs were taken 3 weeks later.
t a density of 1 × 104 was plated in each well which was coated with
Stable NIH/3T3 cell lines at 60% confluence were stimulated with
etermined by Western blotting. (E) Densitometric readings were
k were normalized to that of total Erk. Data are representative of three
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that from the Vector transfectants. However, the Grb2K56R
transfectants produced numbers and sizes of colonies
equivalent to those produced by the Vector transfectants,
indicating that Grb2K56R lost its oncogenic function in
promoting anchorage-independent growth (Figure 3B).
Vasculogenic mimicry (VM) usually refers to the plas-
ticity of aggressive cancer cells forming de novo
vascular networks [16] and VM formation can be used to
assess cellular transformation, so next we used the VM
assay to confirm the effect of Grb2 SUMOylaiton on the
transformation potential. Consistently, over-expression of
Grb2WT strongly induced formation of vascular-like shape
whereas Grb2K56R did not (Figure 3C).
Since the above results suggested that Grb2 SUMOyla-
tion at K56 is essential for its function in regulation of cell
transformation, we wondered which signaling pathways
(such as ERK, AKT, STAT3 pathways) were affected by
Grb2 SUMOylation. Stable NIH/3T3 cell lines were treated
with 5 μg/ml of Doxycycline for 24 or 36 hours as reported
[17,18]. Grb2K56R cells were incapable of maintaining the
ERK activity while Grb2WT cells still kept higher ERK activ-
ity with the treatment of Doxycycline for 24 h (Figure 3D
& E). However, pAKT and pSTAT3 showed no much
change among these cell lines (data not shown). Taken
together, these data demonstrated that SUMOylation of
Grb2 at K56 is required for up-regulation of ERK activa-
tion, which is crucial for cellular transformation.
SUMOylation of Grb2 promotes migration and
tumorigenesis via upregulation of the ERK activities
To verify the Grb2 dependence of the ERK activities and
oncogenic phenotypes, endogenous Grb2 was silenced
(Figure 4A-B) before Grb2WT and Grb2K56R were rein-
troduced respectively in the murine fibroblast cell line
NIH/3T3 (Figure 4C) and the murine colon cancer cell
line CMT-93 (Figure 4D) using the lentiviral vector
system. Then we tested the ERK activity after NIH/3T3
stable cell lines were treated with Doxycyline and CMT-
93 stable cell lines treated with EGF. As expected, ERK
activities were markedly reduced by Grb2 knock-down in
both NIH/3T3 and CMT-93 cells. Ectopic re-expression
of Grb2WT in NIH/3T3 cells retained higher ERK activ-
ities compared to those of Grb2K56R after treatment with
Doxycycline for 24 h (Figure 4C). Similarly, Grb2K56R
reduced EGF-induced phosphorylation of ERK in CMT-
93 cells (Figure 4D). These data further confirmed that
blockage of SUMOylation of Grb2 at K56 impairs Grb2-
regulated ERK activities.
To investigate whether the enhanced ERK activities me-
diated by Grb2 SUMOylation also influences cell migra-
tion, wound healing assay [19] and RTCA (real-time
cell analysis) assay [20] were carried out to evaluate
cell motility. As reported previously [21], knock-down ofGrb2 impaired cell motility, which is consistent with the
decrease of the ERK activities in Grb2-silencing NIH/3T3
or CMT-93 cells. Furthermore, ectopic re-expression of
Grb2WT but not Grb2K56R in the endogenous Grb2-
silencing NIH/3T3 or CMT-93 cells recovered the im-
paired cell migratory behavior (Figure 4E-G). We also
determined whether the ERK activities controlled by
Grb2 SUMOylation were associated with tumorigenesis
in CMT-93 cancer cells. As shown in Figure 4H and
Additional file 1, knockdown of endogenous Grb2 effect-
ively suppressed the size of colonies, which was rescued
by ectopic re-expression of Grb2WT but not Grb2K56R. In
order to verify the role of Grb2 SUMOylation in tumori-
genesis in vivo, the four CMT-93 cell lines were injected
subcutaneously into nude mice. Consistent with the
results of colony formation experiment, knockdown of
endogenous Grb2 dramatically suppressed tumor growth,
which was rescued by ectopic re-expression of Grb2WT
but not Grb2K56R (Figure 4I). Thus, our data revealed that
Grb2 SUMOylation is required for promoting migration
and tumorigenesis by up-regulation of the ERK activities.
Grb2 SUMOylation increases its binding to Sos1
Our above results have proven the new concept that
Grb2 SUMOylation is crucial for maintaining the ERK
activities, sequentially resulting in cellular transform-
ation, enhanced migration and tumorigenesis, so next
we want to get insight into the underlying molecular
mechanisms. One possibility is that Grb2 SUMOylation
affects its binding with some important proteins that are
closely related with the activation of the RAS/MEK/
MAPK signaling pathway. To verify this hypothesis, we
selected 6 target proteins including EGFR, SHP2, FAK,
Sos1, PTPα and Gab1, which are all considered control-
ling the ERK activities and cell phenotypes (Additional
file 2). EGFR was one of the most important RTKs in
recruiting Grb2-Sos1 complex to regulate ERK activity
in response to extracellular EGF stimulation [8,22]. Sos1,
as described before, was the famous guanine nucleotide-
exchange factors in directing exchange of Ras-GDP to
Ras-GTP to activate ERK by binding to Grb2 SH3
domains [23]. SHP2 (Src Homology 2 containing protein
tyrosine phosphatase 2) is an important tyrosine phos-
phatase involved in various pathophysiological processes
[24] through binding with Grb2 to regulate the ERK,
Akt, STAT3 signaling pathways [25-27]. Gab1 (Grb2-as-
sociated-Binding protein 1) binds to Grb2 C-SH3 domain
regulating the ERK and PI3K/Akt signaling pathways in
the presence of different signal factors [28,29]. The phos-
phorylated FAK (Focal Adhesion Kinase) binds to Grb2
SH2 domain in the help with Src regulating ERK signaling
pathway and especially cell mobility [30]. PTPα (Re-
ceptor protein-tyrosine phosphatase α) also binds to Grb2
to regulate the ERK activity and tumorigenesis [31-34].
Figure 4 (See legend on next page.)
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Figure 4 SUMOylation of Grb2 promotes migration and tumorigenesis by upregulation of the ERK activities. (A-B) Endogenous Grb2 in
the murine fibroblast cell line NIH/3T3 (A) and the murine colon cancer cell line CMT-93 (B) was knockdown by a short hairpin RNA targeting
Grb2 3′UTR (shGrb2) by using the lentiviral vector pLKO.1 system. Grb2WT and Grb2K56R were reintroduced respectively into these stable
Grb2-silencing NIH/3T3 and CMT-93 cells by the lentiviral system. (C) The ERK activities in stable NIH/3T3 cell lines treated with 5 μg/ml of
Doxycycline for 24 or 48 hours were determined by Western blotting. (D) Serum-starved stable CMT-93 cell lines were stimulated with 100 ng/ml of
EGF for 5 or 10 minutes and the ERK activities were determined by Western blotting. (E-F) Cell motility was determined by wound healing assay in
μ-Dish for NIH/3T3 (E) and CMT-93 (F) stable cell lines. (G) The kinetic information about the migration of CMT-93 stable cell lines was
recorded using the x CELLigence RTCA-DP system. (H) Stable CMT-93 cell lines were seeded in 2 ml of medium containing 20% FBS with
0.35% agar at 5 × 103 cells/well and layered onto the base. The photographs were taken 2 weeks later. Images are representative of three
independent experiments. (I) Stable CMT-93 cell lines (2 × 106) were injected subcutaneously into male BALB/c nude mice (n = 5) individually. The
sizes of tumors were measured at day 14, 17 and 20 after injection and the tumors were weighed.
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hanced with the increase of the amount of SUMO1/Ubc9
plasmids in HEK293T transfection system (Figure 2C).
Thus, we took advantage of gradually increasing the
amount of SUMO1/Ubc9 along with equal amount of
Flag-Grb2 to observe the changes in binding between
SUMO-Grb2 and interacting proteins. Flag antibody
was used for co-immunoprecipitation of Flag-Grb2 and
the following Western blotting was conducted to detect
its interacting proteins. Firstly, we questioned if Grb2
SUMOylation could influence its SH2 domain binding
with EGFR and SHP2. Before harvested, transfected
HEK293T cells were serum-starved for 20 h and then
stimulated with EGF for 5 min (Figure 5A) or serum
for 20 min (Figure 5B). As shown in Figure 5A-B, p-
EGFR, p-SHP2 and FAK displayed no changes in binding
with Grb2 with the increased amount of SUMO1/Ubc9
plasmids. Surprisingly, we observed that Sos1 bound to
Grb2 was gradually increased whereas PTPα or Gab1
bound to Grb2 was not changed with the increase of
the amount of SUMO1/Ubc9 plasmids (Figure 5C). To
further validate this finding, we examined the effect of the
SUMO-site mutant Flag-Grb2K56R on the binding with
Sos1. Indeed, Grb2K56R did not show an evidently in-
creased binding capability with Sos1 when the amount
of SUMO1/Ubc9 plasmids increased (Figure 5D). More-
over, to exclude the possibility that SUMOylation en-
hancing the formation of Grb2-Sos1 complex is attributed
to Sos1 SUMOylation, we investigated whether endogen-
ous Sos1 can be SUMOylated by using in vivo Ni2+-NTA
pulldown (Figure 5E) and immunoprecipitation (Figure 5F)
assays. As shown in Figure 5E-F, endogenous Sos1
was not SUMOylated while endogenous Grb2 SUMOyla-
tion occurred as positive controls here. Taken together,
our results demonstrated that Grb2 SUMOylation in-
creases its binding to Sos1, thereby leading to the activa-
tion of the RAS/MEK/MAPK signaling pathway.
Discussion
Grb2, containing one SH2 and two SH3 domains, works
as a powerful adaptor protein by linking hundreds ofadaptive signal factors to activated EGFR, which drive
them to locate on the membrane. Initially, Grb2 was
characterized to participate in cell proliferation, however,
the recent reports indicated that Grb2 also plays a role
in tumorigenesis and cell motility [15], which are con-
sistent with our concept that Grb2 SUMOylation pro-
motes cell migration and tumorigenesis. In this study, we
found that Grb2 was mainly SUMOylated at K56, which
could be removed by SENP1. It should be noted that
K56 may also be modified by acetylation or ubiquiti-
nation, however we did not observe obvious obvious
acetylation and ubiquitination for Grb2 (data not shown).
Grb2 SUMOylation plays an important role in strength-
ening tumorigenesis and cell migratory capacity by en-
hancing the ERK activities. Moreover, our results revealed
that the enhancement of ERK activities was attributed
to the SUMO1 modification of Grb2 facilitating Grb2
binding with Sos1 other than other interacting proteins
such as EGFR, SHP2, FAK, PTPα and Gab1, which
are all considered connecting the ERK activities and
cell phenotypes.
As the activator of Ras/MEK/ERK pathway, Grb2-
Sos1 complex is crucial for regulating cell proliferation,
tumorigenesis, early embryonic stem cell fate and nor-
mal development [35]. Grb2 and Sos1 function inter-
dependently on each other, thus, mutations on Sos1 or
unusual phosphorylation on Grb2 would lead to aberrant
physiological events such as Noonan syndrome [36,37]
and tumorigenesis [11]. Hence, the anti-cancer strategies
targeting Grb2 is also focused on the disruption of the
Grb2-Sos1 complex by blocking the interaction of Grb2
SH3 domain with Sos1 [38,39]. In this study, we discov-
ered the formation of Grb2-Sos1 complex is finely regu-
lated by SUMO1 modification at K56 of Grb2. As known,
Grb2 recognizes proline-rich sequences of Sos1 by means
of its SH3 domains, leading to Ras activation, whereas
K56 of Grb2 is located in the linker region between
the N-SH3 domain and the SH2 domain. The exact mech-
anism underlying Grb2 SUMOylation at K56 recruiting
more Sos1 to form SUMO-Grb2-Sos1 complex deserves
further study.
Figure 5 (See legend on next page.)
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Figure 5 SUMOylation of Grb2 increases its binding with Sos1. (A-B) HEK293T cells were co-transfected with the indicated plasmids. 24 hours
later, cells were subjected to serum deprivation for 20 hours, followed the treatments with or without 100 ng/ml of EGF (A) or 10% serum (B) for
the indicated time. Cell lysates were immunoprecipitated and subsequently immunoblotted with indicated antibodies. (C-D) HEK293T cells were
co-transfected with the indicated plasmids and harvested after 48 hours. Cell lysates were immunoprecipitated and subsequently immunoblotted
with the indicated antibodies. Densitometric readings were obtained with ImageJ V1.45 software. (E-F) Sos1 was not SUMOylated.
HEK293T cells were co-transfected with the indicated plasmids and analyzed for SUMOylation by Ni2+-NTA pulldown (E) or immunoprecipitation (F).
SUMOylated Grb2 was used as a positive control of SUMOylation, and mouse IgG as a negative control in immunoprecipitation.
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In summary, as shown in Figure 6, our data unravel a new
regulatory mechanism that Grb2 SUMOylation plays an
important role in enhancing the Ras/MEK/ERK pathway.
Grb2 SUMOylation at K56 facilitates the formation of
Grb2-Sos1 complex via recruiting more Sos1, leading to
the ERK activation and consequently promoting cell mi-
gration and tumorigenesis. Our findings might also have
significant impact on cancer therapy, as dysregulation




Antibodies against Grb2 (#3972), Sos1 (#5890), SUMO-1
(#4930), Phospho-P44/42-Erk1/2 (#4370), P44/42-Erk1/2
(137F5), β-Actin (13E5) were from Cell signaling Tech-
nology. GAPDH (ab37168) antibody was from ABCAM.
Normal mouse IgG antibody (sc-2025) was from Santa
Cruz Biotechnology (Santa Cruz, CA). Phospho-SHP2
pY542 (#2184-1), phospho-EGFR pY1068 (#1138-1)Figure 6 A schematic model of Grb2 SUMOylation-regulated ERK p
recruiting more Sos1 to form Grb2-Sos1 complex, and consequently pr
Solid line––Strong.antibodies were from EPITOMICS. Anti-Flag (M2) and
anti-HA mouse antibodies were from Sigma. Protein G
Plus/Protein A agarose suspension (#IP05) and Recombin-
ant Human Epidermal Growth Factor (rHu EGF) were
purchased from Calbiochem. Doxycycline Hyclate (D9891)
and Puromycin (P8833) were from Sigma.
Plasmids
The Grb2 cDNA was cloned and sequenced, and then
sub-cloned into the vector pCMV-Tag2b. The Flag-Grb2
was cloned into the lentiviral vector carrying Puromycin
and EGFP genes [13]. The Grb2 cDNA was cloned into
the vector pGEX4T1 to generate a construct GST-Grb2.
The shRNA sequence targeting mouse Grb2 3′UTR
(shGrb2) was obtained from Sigma ‘Mission shRNA’
online: 5′-GCATGATGTTTAAGGCCACAT-3′ at 1270
site. The shRNA was cloned into pLKO.1 vector. The
FAK cDNA was cloned into the vector pCMV-HA to
generate the HA tagged FAK. The pE1E2S1 plasmid was
obtained from Dr. Jiemin Wong in East China Normal
University.athway. SUMOylation of Grb2 at K56 enhances the ERK activity via
omoting cell migration and tumorigenesis. Dashed line––Weak;
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HEK293T, 293FT, NIH/3T3 and CMT-93 cell lines were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal calf serum (Hyclone) at 37°C in a 5%
CO2 humidified incubator. Cell transfection was per-
formed using Lipofectamine 2000 (Invitrogen).
SUMOylation assays
Grb2 SUMOylation was analysed in HEK293T by the
method of in vivo SUMOylation assay using Ni2+-NTA
beads as previously described [12,19]. In vitro E.coli BL21-
based SUMOylation assay with the plasmid pE1E2S1 was
conducted as previously described [14].
Soft agar colony assay
The effect of Grb2WT and Grb2K56R on cellular trans-
formation and tumorigensis was assessed by using a soft
agar colony assay as previously described [13]. Briefly,
this assay was performed in 6-well plates with a base of
2 ml of medium containing 5% (for NIH/3T3 stable cell
lines) or 20% (for CMT-93 stable cell lines FBS) with
0.6% Bacto agar (Amresco). Cells were seeded in 2 ml of
medium containing 5% or 20% FBS with 0.35% agar at
5 × 104 (for NIH/3T3) or 5 × 103 (for CMT-93) cells/well
and layered onto the base. The photographs of the cells
growing in the plate and of the colonies developed in
soft agar were taken at day 21 (for NIH/3T3) or 14 (for
CMT-93). Three independent experiments were performed
in triplicate.
Vasculogenic mimicry
The vasculogenic mimicry experiment of stable NIH/
3T3 cell lines was carried out usingμ-Slide Angiogenesis
Kit (IBIDI) according to the manufacturer’s protocol.
Cells at a density of 1 × 104 were plated in each well
which was coated with matrigel and pictures were taken
with microscope 20 hours later.
Migration assay by wound healing
This method for analysis of migration was conducted as
described previously [19]. Briefly, 1 × 104 (for CMT-93)
or 2 × 104 (for NIH3T3) of cells were plated into the μ-
Dish (35 mm high, purchased from IBIDI ) and cultured
overnight to ensure adhered. A clear area was created
by removing the Culture-Insert from the μ-Dish, and
photos were taken as indicated time until the wound
was healed.
Migration assay by RTCA-DP
Migration assay by using the xCELLigence RTCA-DP
system (Roche, Mannheim, Germany) was described in
our previous study [20]. Briefly, 5 × 103 of serum-starved
stable CMT-93 cell lines were resuspended in 100 μl
of serum free medium and added into the pre-equilibratedupper chamber of the CIM-plate along with the bottom-well
plate containing 2% FBS DMEMmedium for migration.
Xenografted tumor model in vivo
Stable CMT-93 cell lines (2 × 106, suspended in 100 ster-
ile PBS) were harvested and injected subcutaneously into
5-week-old male BALB/c nude mice (n = 5) individually.
Two weeks after injection, the tumors were measured
every 3 days. At the experimental endpoint, mice were
sacrificed and the tumors were dissected, weighed and
photographed.
Immunoprecipitation
Cells transfected with the indicated plasmids were lysed in
the RIPA buffer (50 mM Tris–HCl pH7.4, 150 mM NaCl,
1% NP-40, 20 mM N-ethylmaleimide, and complete pro-
tease inhibitor cocktail tablet) on ice. About 500–1000 μg
cell lysates were incubated with 30 μl of Protein A/G
agarose and Flag or HA antibodies overnight at 4°C on
an verticle roller. The next day, the Plus A/G beads were
washed 4 times with RIPA buffer and dissolved in 1×
protein loading buffer (50 mM Tris–HCl pH6.8, 2% SDS,
0.1% Bromophenol Blue, 10% Glycerol, 1.5% DTT) for
Western Blot analysis.
Western blot
The proteins either from whole cell lysates in the
SDS-lysis buffer (10 mM Tris–HCl, pH 7.4, 1% SDS, and
1 mM Na3VO4), or derived from immunoprecipitations,
were resolved via SDS/PAGE gels then transferred to a
polyvinylidene difluoride (PVDF) membrane. The mem-
brane was subsequently probed with the indicated pri-
mary antibodies and second antibodies indicated, and
then exposured in ImageQuant LAS 4000 (GE) after
incubating with ECL substrate.
Additional files
Additional file 1: (A) More representive images from the colony
formation experiments (Figure 4H) were shown. (B) The number of
colonies was counted. The colony sizes but not colony numbers were
different among indicated cell lines.
Additional file 2: Schematic representation of the binding between
Grb2 and 6 selected target proteins, including EGFR, SHP2, FAK,
Sos1, PTPα and Gab1.Abbreviations
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